| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TFE3 |
| Uniprot No | P19532 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 166-254aa |
| 氨基酸序列 | RPPPAQVPREVLKVQTHLENPTRYHLQQARRQQVKQYLSTTLGPKLASQA LTPPPGPASAQPLPAPEAAHTTGPTGSAPNSPMALLTIG |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与TFE3重组蛋白相关的文献示例(注：文献标题与作者为虚拟信息，仅用于示例)：
---
1. **文献名称**：*Cloning and Functional Analysis of Recombinant TFE3 Protein in Renal Cell Carcinoma*
**作者**：Smith A, et al.
**摘要**：该研究通过原核表达系统成功克隆并纯化了人源TFE3重组蛋白，证实其在肾癌细胞系中通过调控下游靶基因(如MITF、溶酶体相关基因)促进肿瘤增殖，并利用荧光素酶报告基因验证其转录活性。
---
2. **文献名称**：*TFE3 Fusion Proteins Drive Chromatin Remodeling via Recombinant Expression Systems*
**作者**：Li X, et al.
**摘要**：文章构建了TFE3与PRCC基因的融合重组蛋白，发现其异常激活mTORC1信号通路，并通过染色质免疫沉淀(ChIP)证明融合蛋白特异性结合启动子区域，导致细胞周期失调，为Xp11易位性肾癌的机制提供了新见解。
---
3. **文献名称**：*Structural Characterization of Recombinant TFE3 DNA-Binding Domain by X-ray Crystallography*
**作者**：Yamamoto K, et al.
**摘要**：通过X射线晶体学解析了TFE3蛋白DNA结合域的三维结构，揭示了其与DNA相互作用的特异性氨基酸残基，为设计靶向TFE3异常活性的小分子抑制剂奠定结构基础。
---
**备注**：以上文献为模拟内容，实际研究需通过PubMed或Google Scholar检索关键词“TFE3 recombinant protein”“TFE3 fusion”“TFE3 structure”等获取真实文献(如Nature、Cancer Cell等期刊的论文)。
TFE3 recombinant protein is derived from the TFE3 gene, which encodes a member of the microphthalmia-associated transcription factor (MiT/TFE) family. This family, including TFE3. MITF, TFEB, and TFEC, regulates lysosomal biogenesis, cellular metabolism, and mitochondrial homeostasis by binding to CLEAR (Coordinated Lysosomal Expression and Regulation) elements in target gene promoters. TFE3 is notably implicated in chromosomal translocations, particularly in Xp11.2 translocation renal cell carcinoma (tRCC) and alveolar soft part sarcoma (ASPS), where gene fusions (e.g., PRCC-TFE3. ASPSCR1-TFE3) create oncogenic chimeric proteins that drive tumorigenesis.
Recombinant TFE3 proteins are engineered in vitro to study its wild-type or mutant forms. These proteins retain functional domains, including the basic helix-loop-helix leucine zipper (bHLH-LZ) for DNA binding and dimerization, and transactivation domains. Researchers use them to investigate TFE3’s role in cellular pathways, its dysregulation in diseases, and its interaction with co-regulators like mTORC1. which phosphorylates TFE3 to control its cytoplasmic-nuclear shuttling.
Clinically, recombinant TFE3 aids in diagnosing fusion-driven cancers via immunohistochemistry or molecular assays. Therapeutically, it serves as a tool to screen inhibitors targeting TFE3 fusion proteins or to develop gene therapies. Its study also informs lysosomal storage disorders and metabolic diseases linked to MiT/TFE dysfunction. Despite progress, challenges remain in understanding post-translational modifications and context-specific regulatory networks involving TFE3.
×
